Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 27, 2026

Pharma Conference Coverage Services: Real-Time Pharma Intelligence to Power Strategic Decision-Making

View original at finance.yahoo.com
Pharma Conference Coverage Services: Real-Time Pharma Intelligence to Power Strategic Decision-Making DelveInsight provides structured pharma conference coverage solutions designed to help industry leaders to track and interpret critical developments emerging from major healthcare conferences…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • DelveInsight is a leading provider of strategic conference coverage solutions, specializing in tracking, analyzing, and summarizing insights from global healthcare and pharmaceutical events across multiple therapy areas

    80% confidence
  • DelveInsight is a pioneer in providing customized conference coverage services, supporting client needs across indication and therapy area monitoring, inhibitor-specific updates, booth intelligence, KOL insights, phase transitions, and post-conference summaries

    80% confidence
  • The pharmaceutical sector continues to evolve at an unprecedented pace, and missing a pivotal presentation could mean missing emerging efficacy trends, novel mechanisms, or competitor signals shaping tomorrow's market

    80% confidence
  • Clients can track multiple conferences throughout the year under a single therapeutic area, such as Oncology, ensuring continuous year-round competitive and scientific intelligence

    80% confidence
  • DelveInsight's competitive intelligence services equip clients with real-time, accurate insights spanning multiple therapeutic domains including competitor pipelines, clinical trial tracking, gene and cell therapy innovations, market-entry strategies, and regulatory and patent landscapes

    80% confidence
  • In the rare disease space, DelveInsight monitors global R&D progress, competitive developments, and shifting regulatory landscapes to provide tailored insights that guide product positioning and investment strategies

    80% confidence
  • DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences

    80% confidence
  • DelveInsight's conference coverage spans major therapeutic areas from oncology to rare disease, annually covering major conferences such as ASCO, ESMO, ASH, AACR, ATS, ERS, etc.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com